There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux esophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment.

The present technology provides nanoparticles comprising an inorganic core and NAD.sup.+ or NADH, coated with a lipid bilayer, wherein the inorganic core is selected from calcium phosphate or a metal organic framework (MOF); the MOF comprises a transition metal ion coordinated to a coordinating ligand, wherein the transition metal ion is selected from the group consisting of zinc, iron, zirconium, copper, and cobalt ions, and the coordinating ligand is selected from an imidazolate ligand or a carboxylate ligand; and the nanoparticle has an average hydrodynamic diameter of from at least 50 nm to less than 1000 nm. Pharmaceutical compositions incorporating such nanoparticles and methods of treating sepsis and/or inflammation with such particles are also provided.

The present technology provides nanoparticles comprising an inorganic core and NAD.sup.+ or NADH, coated with a lipid bilayer, wherein the inorganic core is selected from calcium phosphate or a metal organic framework (MOF); the MOF comprises a transition metal ion coordinated to a coordinating ligand, wherein the transition metal ion is selected from the group consisting of zinc, iron, zirconium, copper, and cobalt ions, and the coordinating ligand is selected from an imidazolate ligand or a carboxylate ligand; and the nanoparticle has an average hydrodynamic diameter of from at least 50 nm to less than 1000 nm. Pharmaceutical compositions incorporating such nanoparticles and methods of treating sepsis and/or inflammation with such particles are also provided.

The invention relates to derivatives of apramycin-based aminoglycoside antibacterial drugs modified in positions C5 and/or C6 and O5 and/or O6. The modifications impart favourable properties regarding increased selectivity and retention of activity in the presence of resistance determinants of the AAC(3) class. The invention further relates to said compounds for use in the therapy of bacterial infection by systemic administration, especially in instances where the infection is caused by a pathogen comprising a resistance determinant of the AAC(3) class, in particular AAC(3)-IV.

Topical cream or ointment medications formulated by blending admixtures of various concentrations of active ingredients with a plurality of inactive excipient ingredients for treating acne and a variety of other similar skin ailments including, folliculitis, rosacea, boil, skin-flaking, minor wounds, cuts, and adverse skin-issues related to use of covid-19 protective face-masks covered-area rashes, acne and non-lethal insect bites.

Topical cream or ointment medications formulated by blending admixtures of various concentrations of active ingredients with a plurality of inactive excipient ingredients for treating acne and a variety of other similar skin ailments including, folliculitis, rosacea, boil, skin-flaking, minor wounds, cuts, and adverse skin-issues related to use of covid-19 protective face-masks covered-area rashes, acne and non-lethal insect bites.

Topical cream or ointment medications formulated by blending admixtures of various concentrations of active ingredients with a plurality of inactive excipient ingredients for treating acne and a variety of other similar skin ailments including, folliculitis, rosacea, boil, skin-flaking, minor wounds, cuts, and adverse skin-issues related to use of covid-19 protective face-masks covered-area rashes, acne and non-lethal insect bites.

The present disclosure is concerned with liposomal formulations comprising troponoid compounds and methods of using same in the treatment of, for example, viral infections, antimicrobial infections, cancer, inflammatory diseases, and cardiovascular diseases. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with liposomal formulations comprising troponoid compounds and methods of using same in the treatment of, for example, viral infections, antimicrobial infections, cancer, inflammatory diseases, and cardiovascular diseases. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure is concerned with liposomal formulations comprising troponoid compounds and methods of using same in the treatment of, for example, viral infections, antimicrobial infections, cancer, inflammatory diseases, and cardiovascular diseases. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.